Pramlintide
Also known as: Symlin, Amylin Analog
Overview
Pramlintide (brand name Symlin) is a synthetic 37-amino acid analog of human amylin with three proline substitutions that prevent the spontaneous aggregation and fibrillation that occurs with native amylin. It was FDA-approved in 2005 as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes to improve postprandial glycemic control. Beyond glycemic management, pramlintide produces modest but consistent weight loss (1–2 kg in clinical trials) through appetite suppression and gastric emptying delay.
Mechanism of Action
Pramlintide mimics endogenous amylin by binding amylin receptors (calcitonin receptor/RAMP complexes) in the area postrema and hypothalamus. It suppresses postprandial glucagon secretion, slows gastric emptying, and promotes satiety via central nervous system pathways. The combination with mealtime insulin addresses two complementary postprandial metabolic processes: glucose uptake stimulation (insulin) and glucagon suppression/gastric emptying delay (pramlintide), producing more physiological postprandial glucose curves than insulin alone.
Potential Benefits
- Improved postprandial glycemic control in T1D and T2D
- Modest weight loss (1–2 kg)
- Reduced postprandial glucagon excursions
- A1C reduction of 0.5–0.7% as insulin adjunct
- Reduced meal insulin requirements
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 15 mcg before meals (T1D) titrating upward |
| Intermediate | 60 mcg before meals (T1D target) or 60 mcg (T2D start) |
| Advanced | 120 mcg before meals (T2D target) |
| Cycle Duration | Chronic with meals |
FDA-approved (Symlin) adjunct for insulin-treated T1D and T2D. Never mix in same syringe with insulin. Reduce rapid insulin ~50% when starting.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection ~30-40%
Inject abdomen or thigh immediately before major meals. Separate from insulin injection site by ≥2 inches.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Pramlintide:
Insulin + Pramlintide (FDA-approved)
Symlin adjunct to mealtime insulin in T1D/T2D — improves postprandial glucose control.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate 2-8°C before use; room temperature up to 30 days after first use |
|---|
No reconstitution needed. Do not freeze.
Need exact syringe measurements?
Amino Acid Sequence
Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (with Pro substitutions at 25,28,29)
Side Effects & Safety
- Nausea (most common, especially during initiation)
- Hypoglycemia when used with insulin (requires insulin dose reduction)
- Vomiting
- Anorexia
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Drug Interactions
- Insulin (rapid-acting):
FDA Safety Information
FDA Boxed Warning: Risk of insulin-induced severe hypoglycemia, particularly in patients with type 1 diabetes; reduce rapid-acting insulin doses by 50% when initiating.
Pharmacokinetics
| Half-Life | ~48 minutes |
|---|---|
| Storage | Refrigerate pens at 2-8°C. Once opened, may be kept at room temperature (<25°C) for up to 30 days. Do not freeze. |
Synergistic Compounds
The following compounds have been studied alongside Pramlintide for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.